Drugs / ELV001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07409103 | Feb 2026 → Apr 2027 expected | rheumatoid arthritis | Elevara Medicines Limited | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-16 | Elevara Medicines Limited | Elevara Medicines Doses First Patient in Phase 2b START-SYNERGY Trial of ELV001 in Rheumatoid Arthritis Patients with Incomplete Response to TNFi elevara.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ELV001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07409103 ↗ |